# Apatinib: TKI Mechanism, Clinical Efficacy & Research Guide
> Explore the mechanism, efficacy in gastric cancer and HCC, and future combination therapies of Apatinib (VEGFR-2 TKI) in this clinical research overview.

Tags: apatinib, tyrosine-kinase-inhibitor, oncology, gastric-cancer, hcc, vegfr-2, cancer-research, angiogenesis
## Apatinib: A Novel TKI
*   Focus: Mechanism, Clinical Efficacy, and Future Directions.
*   Context: Clinical Research Overview.

## Mechanism of Action
*   Type: Small-molecule tyrosine kinase inhibitor (TKI).
*   Target: Highly selective for Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2).
*   Function: Inhibits tumor angiogenesis, endothelial cell migration, and proliferation.

## Chemical Properties & Structure
*   Delivery: Oral administration.
*   Format: Small Molecule TKI with highly potent binding affinity.

## Clinical Efficacy: Gastric Cancer
*   Clinical Source: Li et al., J Clin Oncol 2016.
*   Key Result: OS increased to 6.5 months (Apatinib) vs 4.7 months (Placebo).
*   PFS Result: 2.6 months (Apatinib) vs 1.8 months (Placebo).

## Efficacy in Hepatocellular Carcinoma (HCC)
*   Clinical Source: HELP Study (Qin et al., JAMA Oncol 2021).
*   OS Result: 8.7 months (Apatinib) vs 6.8 months (Placebo).
*   PFS Result: 4.5 months (Apatinib) vs 1.9 months (Placebo).

## Broad Spectrum Application
*   NSCLC: Prolonged PFS in non-squamous advanced cases.
*   Breast Cancer: Potential in non-triple-negative metastatic cases.
*   Ovarian Cancer: Improved PFS when combined with chemotherapy (APPROVE trial).

## Safety Profile & Adverse Events
*   Common AEs: Hypertension (48%), Proteinuria (45%), Fatigue (30%), Leukopenia (28%), Hand-foot Syndrome (27%).
*   Management: Weekly blood pressure monitoring and regular urine protein checks.

## Pharmacokinetics (PK)
*   Absorption (Tmax): 3 - 4 Hours.
*   Half-life (t1/2): ~9 Hours.
*   Metabolism: Hepatic (CYP3A4).
*   Excretion: ~77% via feces.

## Synergy: Immunotherapy Combination
*   Concept: Normalizing tumor vasculature to enhance immune cell infiltration.
*   Synergy: Effective when combined with PD-1 inhibitors like Camrelizumab.

## Key Takeaways
*   Mechanism: Selective VEGFR-2 inhibition.
*   Indications: Established in Gastric Cancer and HCC; emerging in Lung, Breast, and Ovarian.
*   Future: Focus on combination therapies with immune checkpoint inhibitors.
---
This presentation was created with [Bobr AI](https://bobr.ai) — an AI presentation generator.